MARKET

APLT

APLT

Applied
NASDAQ

Real-time Quotes | Nasdaq Last Sale

41.48
-1.30
-3.04%
Opening 10:26 02/24 EST
OPEN
41.87
PREV CLOSE
42.78
HIGH
42.24
LOW
40.89
VOLUME
38.75K
TURNOVER
--
52 WEEK HIGH
57.39
52 WEEK LOW
7.95
MARKET CAP
707.33M
P/E (TTM)
-81.0156
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of APLT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average APLT stock price target is 50.67 with a high estimate of 65.00 and a low estimate of 43.00.

EPS

APLT News

More
  • The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and Ennis
  • Zacks · 3d ago
  • US Dollar Flexes Muscles Against Other Currencies: 5 Winners
  • Zacks · 4d ago
  • 3 Top Biotech Stocks to Buy in February
  • MotleyFool.com · 02/09 13:29
  • The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data
  • Benzinga · 02/05 12:43

Industry

Biotechnology & Medical Research
-2.02%
Pharmaceuticals & Medical Research
-2.09%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About APLT

Applied Therapeutic, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of product candidates against validated molecular targets in indications of unmet medical need. Its molecular target is aldose reductase (AR), which is an enzyme and rate-limiting step in the polyol pathway. Its lead product candidate, AT-001, is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), a fatal fibrosis of the heart. Its AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). It is also developing AT-001 for diabetic peripheral neuropathy (DPN), a debilitating neurodegenerative disease.
More

Webull offers kinds of Applied Therapeutics Inc stock information, including NASDAQ:APLT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APLT stock news, and many more online research tools to help you make informed decisions.